Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

State of the Science Summit - Lung Cancer: Chaired by Jobelle Baldonado, MD, and Jhanelle Gray, MD

February 1st 2024

State of the Science Summit - Lung Cancer: Chaired by Jobelle Baldonado, MD, and Jhanelle Gray, MD

State of Science Summit - Lung Cancer: Chaired by Shetal Patel, MD, PhD

January 31st 2024

State of Science Summit - Lung Cancer: Chaired by Shetal Patel, MD, PhD

FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC

January 31st 2024

The FDA granted priority review to a sNDA seeking the approval of alectinib as adjuvant treatment after surgery for early-stage ALK-positive NSCLC.

Biomarker Identification Drives Research and Drug Development in NSCLC and SCLC

January 29th 2024

Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.

Future Perspectives on the Treatment of NSCLC

January 26th 2024

Dr Edgardo Santos highlights key takeaways from the presented data and provides insights into how these findings could shape the future landscape of healthcare directions.

Dato-DXd for Treating Advanced NSCLC

January 26th 2024

Benjamin Levy, MD, reviews clinical data on Dato-DXd in patients with advanced NSCLC and their practical implications.

EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights

January 26th 2024

Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).

Sacituzumab Govitecan Fails to Generate Survival Benefit in Advanced NSCLC

January 23rd 2024

The phase 3 EVOKE-01 trial did not meet its primary end point of significantly improved OS with sacituzumab govitecan vs docetaxel in pretreated NSCLC.

Porter Details Future Directions For Treating Patients With KRAS G12C-Mutated NSCLC

January 22nd 2024

Jason Porter, MD, discusses the progress in the development of treatment options for patients with KRAS G12C-mutated non–small cell lung cancer.

T-DXd in HER2 Mutated Advanced NSCLC

January 22nd 2024

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC

January 19th 2024

Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.

Expert Perspectives on the Latest TROPION-Lung01 Data

January 19th 2024

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.

State of the Science Summit - Lung Cancer: Chaired by Nisha A. Mohindra, MD

January 19th 2024

State of the Science Summit - Lung Cancer: Chaired by Nisha A. Mohindra, MD

Sequential Treatment With Telomere-Targeted Therapy, Checkpoint Inhibition Produces High DCR in NSCLC

January 18th 2024

Treatment with THIO followed by cemiplimab-rwlc led to a high DCR regardless of dose level in patients with pretreated non–small cell lung cancer.

Molecular Testing in Advanced NSCLC

January 18th 2024

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

Dr Bazhenova on the Need for Comprehensive Molecular Testing in Unresectable NSCLC

January 18th 2024

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

FDA Accepts PMA Application Seeking Approval of TTFields Therapy in NSCLC for Filing

January 18th 2024

A PMA application seeking approval of TTFields to standard therapies in patients with non–small cell lung cancer has been accepted for filing by the FDA.

Continued Investigations are Pertinent for FDA Approvals in the Treatment of Patients With EGFR-mutated NSCLC

January 18th 2024

Jason Porter, MD, discusses the implications of adjuvant EGFR TKI use, the importance of the potential FDA approval of osimertinib in EGFR+ NSCLC, & more.

European Commission Approves Subcutaneous Atezolizumab With Enhanze for Several Cancers

January 16th 2024

The European Commission granted marketing authorization for SC atezolizumab co-formulated with Enhanze for all approved indications of IV atezolizumab.

Rate of End-of-Life Immunotherapy Is on the Rise in Advanced Melanoma, NSCLC, RCC

January 15th 2024

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.